Citation of this article
Corresponding Author of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (3653)
All Articles published online
|
Apr 7, 2005 (publication date) through Mar 31, 2025
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Spadaro A, Ajello A, Morace C, Zirilli A, D’arrigo G, Luigiano C, Martino F, Bene A, Migliorato D, Turiano S, Ferraù O, Freni MA. Serum chromogranin-A in hepatocellular carcinoma: Diagnostic utility and limits. World J Gastroenterol 2005; 11(13): 1987-1990 [PMID: 15800991 DOI: 10.3748/wjg.v11.i13.1987] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v11/i13/1987.htm |
| Number | Citing Articles |
| 1 |
Kunal Kapoor, Nour Eissa, Diane Tshikudi, Charles N Bernstein, Jean-Eric Ghia. Impact of intrarectal chromofungin treatment on dendritic cells-related markers in different immune compartments in colonic inflammatory conditions. World Journal of Gastroenterology 2021; 27(47): 8138-8155 doi: 10.3748/wjg.v27.i47.8138
|
| 2 |
Anton L. Evdonin, Marina G. Martynova, Olga A. Bystrova, Irina V. Guzhova, Boris A. Margulis, Natalia D. Medvedeva. The release of Hsp70 from A431 carcinoma cells is mediated by secretory-like granules. European Journal of Cell Biology 2006; 85(6): 443 doi: 10.1016/j.ejcb.2006.02.008
|
| 3 |
Graeme Eisenhofer, Christina Pamporaki, Jacques W M Lenders. Biochemical Assessment of Pheochromocytoma and Paraganglioma. Endocrine Reviews 2023; 44(5): 862 doi: 10.1210/endrev/bnad011
|
| 4 |
S. Massironi, M. Fraquelli, S. Paggi, A. Sangiovanni, D. Conte, V. Sciola, C. Ciafardini, M. Colombo, M. Peracchi. Chromogranin A levels in chronic liver disease and hepatocellular carcinoma. Digestive and Liver Disease 2009; 41(1): 31 doi: 10.1016/j.dld.2008.05.002
|
| 5 |
Paola Di Giacinto, Francesca Rota, Laura Rizza, Davide Campana, Andrea Isidori, Andrea Lania, Andrea Lenzi, Paolo Zuppi, Roberto Baldelli. Chromogranin A: From Laboratory to Clinical Aspects of Patients with Neuroendocrine Tumors. International Journal of Endocrinology 2018; 2018: 1 doi: 10.1155/2018/8126087
|
| 6 |
Jaume Trapé, Xavier Filella, Montse Alsina-Donadeu, Lluïsa Juan-Pereira, Àngels Bosch-Ferrer, Raül Rigo-Bonnin. Increased plasma concentrations of tumour markers in the absence of neoplasia. Clinical Chemistry and Laboratory Medicine 2011; 49(10) doi: 10.1515/CCLM.2011.694
|
| 7 |
Gaetano Bertino, Annalisa Ardiri, Michele Malaguarnera, Giulia Malaguarnera, Nicoletta Bertino, Giuseppe Stefano Calvagno. Hepatocellualar Carcinoma Serum Markers. Seminars in Oncology 2012; 39(4): 410 doi: 10.1053/j.seminoncol.2012.05.001
|
| 8 |
Michael Wagner, Mats Stridsberg, Christer G. B. Peterson, Per Sangfelt, Maria Lampinen, Marie Carlson. Increased Fecal Levels of Chromogranin A, Chromogranin B, and Secretoneurin in Collagenous Colitis. Inflammation 2013; 36(4): 855 doi: 10.1007/s10753-013-9612-4
|
| 9 |
Sofie Lieberoth, Frederik Friis-Hansen, Lennart Friis-Hansen. Paediatric reference ranges for plasma chromogranin A. Annals of Clinical Biochemistry: International Journal of Laboratory Medicine 2023; doi: 10.1177/00045632231202652
|
| 10 |
Detlef K. Bartsch, Elisabeth Maurer, Katharina Holzer. Viszeral- und Allgemeinchirurgie. Springer Reference Medizin 2022; : 1 doi: 10.1007/978-3-662-61724-3_46-1
|
| 11 |
Meera Srivastava, Yelizaveta Torosyan, Mark Raffeld, Ofer Eidelman, Harvey B. Pollard, Lukas Bubendorf. ANXA7 expression represents hormone‐relevant tumor suppression in different cancers. International Journal of Cancer 2007; 121(12): 2628 doi: 10.1002/ijc.23008
|
| 12 |
Johann Guillemot, Marlène Guérin, Erwan Thouënnon, Maité Montéro-Hadjadje, Jérôme Leprince, Hervé Lefebvre, Marc Klein, Mihaela Muresan, Youssef Anouar, Laurent Yon, Stephane Gasman. Characterization and Plasma Measurement of the WE-14 Peptide in Patients with Pheochromocytoma. PLoS ONE 2014; 9(2): e88698 doi: 10.1371/journal.pone.0088698
|
| 13 |
Sara Massironi, Alessandra Zilli, Federica Cavalcoli, Dario Conte, Maddalena Peracchi. Chromogranin A and other enteroendocrine markers in inflammatory bowel disease. Neuropeptides 2016; 58: 127 doi: 10.1016/j.npep.2016.01.002
|
| 14 |
T Szarvas, B Jardin-Watelet, N Bourgoin, M J Hoffmann, P Nyirády, C Oláh, T Széll, A Csizmarik, B Hadaschik, H Reis. High-soluble CGA levels are associated with poor survival in bladder cancer. Endocrine Connections 2019; 8(5): 625 doi: 10.1530/EC-19-0068
|
| 15 |
Valentina Sciola, Sara Massironi, Dario Conte, Flavio Caprioli, Stefano Ferrero, Clorinda Ciafardini, Maddalena Peracchi, Maria Teresa Bardella, Luca Piodi. Plasma chromogranin a in patients with inflammatory bowel disease. Inflammatory Bowel Diseases 2009; 15(6): 867 doi: 10.1002/ibd.20851
|
| 16 |
Detlef K. Bartsch, Elisabeth Maurer, Katharina Holzer. Endokrine Chirurgie. Springer Reference Medizin 2023; : 521 doi: 10.1007/978-3-662-63317-5_46
|
| 17 |
B. Niederle, U.-F. Pape, F. Costa, D. Gross, F. Kelestimur, U. Knigge, K. Öberg, M. Pavel, A. Perren, C. Toumpanakis, J. O''Connor, D. O''Toole, E. Krenning, N. Reed, R. Kianmanesh. ENETS Consensus Guidelines Update for Neuroendocrine Neoplasms of the Jejunum and Ileum. Neuroendocrinology 2016; 103(2): 125 doi: 10.1159/000443170
|
| 18 |
Michele Malaguarnera, Erika Cristaldi, Lisa Cammalleri, Valentina Colonna, Helga Lipari, Alessandra Capici, Andrea Cavallaro, Massimiliano Beretta, Innocenza Alessandria, Salvatore Luca, Massimo Motta. Elevated chromogranin A (CgA) serum levels in the patients with advanced pancreatic cancer. Archives of Gerontology and Geriatrics 2009; 48(2): 213 doi: 10.1016/j.archger.2008.01.014
|
| 19 |
Magdy El-Salhy, Tefera Solomon, Trygve Hausken, Odd Helge Gilja, Jan Gunnar Hatlebakk. Gastrointestinal neuroendocrine peptides/amines in inflammatory bowel disease. World Journal of Gastroenterology 2017; 23(28): 5068-5085 doi: 10.3748/wjg.v23.i28.5068
|
| 20 |
XIII National Congress of Digestive Diseases, Italian Federation of Digestive Diseases – FIMAD Palermo, 29 September – 3 October 2007. Digestive and Liver Disease 2007; 39: S139 doi: 10.1016/S1590-8658(07)80911-X
|
| 21 |
Ulrich-Frank Pape, Aurel Perren, Bruno Niederle, David Gross, Thomas Gress, Frederico Costa, Rudolf Arnold, Timm Denecke, Ursula Plöckinger, Ramon Salazar, Ashley Grossman. ENETS Consensus Guidelines for the Management of Patients with Neuroendocrine Neoplasms from the Jejuno-Ileum and the Appendix Including Goblet Cell Carcinomas. Neuroendocrinology 2012; 95(2): 135 doi: 10.1159/000335629
|
| 22 |
Eleonora Dondossola, Anna Maria Gasparri, Barbara Colombo, Angelina Sacchi, Flavio Curnis, Angelo Corti. Chromogranin A Restricts Drug Penetration and Limits the Ability of NGR-TNF to Enhance Chemotherapeutic Efficacy. Cancer Research 2011; 71(17): 5881 doi: 10.1158/0008-5472.CAN-11-1273
|
| 23 |
Ben Lawrence, Bjorn I. Gustafsson, Mark Kidd, Marianne Pavel, Bernhard Svejda, Irvin M. Modlin. The Clinical Relevance of Chromogranin A as a Biomarker for Gastroenteropancreatic Neuroendocrine Tumors. Endocrinology and Metabolism Clinics of North America 2011; 40(1): 111 doi: 10.1016/j.ecl.2010.12.001
|
| 24 |
Ron Basuroy, Debashis Sarker, Alberto Quaglia, Rajaventhan Srirajaskanthan, John Ramage. Personalized Medicine for Gastroenteropancreatic Neuroendocrine Tumors: A Distant Dream?. International Journal of Endocrine Oncology 2015; 2(3): 201 doi: 10.2217/ije.15.9
|
| 25 |
Giuseppe Coppolino, Davide Bolignano, Laura Rivoli, Giuseppe Mazza, Piera Presta, Giorgio Fuiano. Tumour Markers and Kidney Function: A Systematic Review. BioMed Research International 2014; 2014: 1 doi: 10.1155/2014/647541
|
| 26 |
Masayuki Hijioka, Tetsuhide Ito, Hisato Igarashi, Nao Fujimori, Lingaku Lee, Taichi Nakamura, Robert T. Jensen, Ryoichi Takayanagi. Serum chromogranin A is a useful marker for Japanese patients with pancreatic neuroendocrine tumors. Cancer Science 2014; 105(11): 1464 doi: 10.1111/cas.12533
|
| 27 |
Athanasios Zissimopoulos, Stergios Vradelis, Manolis Konialis, Dimitrios Chadolias, Asimenia Bampali, Theodoros Constantinidis, Eleni Efremidou, George Kouklakis. Chromogranin A as a biomarker of disease activity and biologic therapy in inflammatory bowel disease: a prospective observational study. Scandinavian Journal of Gastroenterology 2014; 49(8): 942 doi: 10.3109/00365521.2014.920910
|
| 28 |
Valentina Ambrosini, Davide Campana, Cristina Nanni, Silvia Cambioli, Paola Tomassetti, Domenico Rubello, Stefano Fanti. Is 68Ga-DOTA-NOC PET/CT indicated in patients with clinical, biochemical or radiological suspicion of neuroendocrine tumour?. European Journal of Nuclear Medicine and Molecular Imaging 2012; 39(8): 1278 doi: 10.1007/s00259-012-2146-4
|
| 29 |
Irvin M. Modlin, Bjorn I. Gustafsson, Steven F. Moss, Marianne Pavel, Apostolos V. Tsolakis, Mark Kidd. Chromogranin A—Biological Function and Clinical Utility in Neuro Endocrine Tumor Disease. Annals of Surgical Oncology 2010; 17(9): 2427 doi: 10.1245/s10434-010-1006-3
|
| 30 |
C. Morace, M. Cucunato, R. Bellerone, G. De Caro, S. Crinò, A. Fortiguerra, F. Spadaro, A. Zirilli, A. Alibrandi, P. Consolo, C. Luigiano, M.L. Resta, O. Ferraù, A. Spadaro. Insulin-like growth factor-II is a useful marker to detect hepatocellular carcinoma?. European Journal of Internal Medicine 2012; 23(6): e157 doi: 10.1016/j.ejim.2012.04.014
|
| 31 |
Sushil K. Mahata, Angelo Corti. Chromogranin A and its fragments in cardiovascular, immunometabolic, and cancer regulation. Annals of the New York Academy of Sciences 2019; 1455(1): 34 doi: 10.1111/nyas.14249
|
| 32 |
Giulia Malaguarnera, Maria Giordano, Isabella Paladina, Massimiliano Berretta, Alessandro Cappellani, Mariano Malaguarnera. Serum Markers of Hepatocellular Carcinoma. Digestive Diseases and Sciences 2010; 55(10): 2744 doi: 10.1007/s10620-010-1184-7
|
| 33 |
Stavros Gkolfinopoulos, Konstantinos Tsapakidis, Konstantinos Papadimitriou, Demetris Papamichael, Panteleimon Kountourakis. Chromogranin A as a valid marker in oncology: Clinical application or false hopes?. World Journal of Methodology 2017; 7(1): 9-15 doi: 10.5662/wjm.v7.i1.9
|
| 34 |
Jaume Trapé, Esther Fernández-Galán, Josep Maria Auge, Marina Carbonell-Prat, Xavier Filella, Sílvia Miró-Cañís, Carolina González-Fernández. Factors influencing blood tumor marker concentrations in the absence of neoplasia. Tumor Biology 2024; 46(s1): S35 doi: 10.3233/TUB-220023
|
| 35 |
Vincenzo Marotta, Maria Chiara Zatelli, Concetta Sciammarella, Maria Rosaria Ambrosio, Marta Bondanelli, Annamaria Colao, Antongiulio Faggiano. Chromogranin A as circulating marker for diagnosis and management of neuroendocrine neoplasms: more flaws than fame. Endocrine-Related Cancer 2018; 25(1): R11 doi: 10.1530/ERC-17-0269
|
| 36 |
Sharjeel Usmani, Marina Orevi, Antonella Stefanelli, Alberto Zaniboni, Ofer Nathan Gofrit, Claudio Bnà, Sonia Illuminati, Giulia Lojacono, Silvia Noventa, Giordano Savelli. Neuroendocrine differentiation in castration resistant prostate cancer. Nuclear medicine radiopharmaceuticals and imaging techniques: A narrative review. Critical Reviews in Oncology/Hematology 2019; 138: 29 doi: 10.1016/j.critrevonc.2019.03.005
|
| 37 |
Christoph Wetz, Tristan Ruhwedel, Imke Schatka, Jane Grabowski, Henning Jann, Giulia Metzger, Markus Galler, Holger Amthauer, Julian M. M. Rogasch. Plasma Markers for Therapy Response Monitoring in Patients with Neuroendocrine Tumors Undergoing Peptide Receptor Radionuclide Therapy. Cancers 2023; 15(24): 5717 doi: 10.3390/cancers15245717
|
| 38 |
Marlène Guérin, Johann Guillemot, Erwan Thouënnon, Alice Pierre, Fatima-Zohra El-Yamani, Maité Montero-Hadjadje, Christophe Dubessy, Rabia Magoul, Isabelle Lihrmann, Youssef Anouar, Laurent Yon. Granins and their derived peptides in normal and tumoral chromaffin tissue: Implications for the diagnosis and prognosis of pheochromocytoma. Regulatory Peptides 2010; 165(1): 21 doi: 10.1016/j.regpep.2010.06.003
|
| 39 |
Elise Glattard, Tommaso Angelone, Jean‐Marc Strub, Angelo Corti, Dominique Aunis, Bruno Tota, Marie‐Hélène Metz‐Boutigue, Yannick Goumon. Characterization of natural vasostatin‐containing peptides in rat heart. The FEBS Journal 2006; 273(14): 3311 doi: 10.1111/j.1742-4658.2006.05334.x
|
| 40 |
EmadA Awad, TarekM Youssef, MohamedO Aly, AzzaA R. Saab. Clinical utility of serum chromogranin A as a marker of hepatocellular carcinoma in chronic hepatitis patients. The Egyptian Journal of Laboratory Medicine 2020; 32(3): 76 doi: 10.4103/ejolm.ejolm_10_21
|
| 41 |
Mats Stridsberg, Barbro Eriksson, Bengt Fellström, Gudjon Kristiansson, Eva Tiensuu Janson. Measurements of chromogranin B can serve as a complement to chromogranin A. Regulatory Peptides 2007; 139(1-3): 80 doi: 10.1016/j.regpep.2006.10.008
|
| 42 |
Aldo Spadaro, Antonino Ajello, Carmelo Luigiano, Carmela Morace, Maria Letizia Resta, Grazia Berlinghieri, Salvatore Campo, Claudio Scisca, Angela Alibrandi, Graziella D’arrigo, Nunziata Alessi, Oscar Ferraù, Maria Antonietta Freni. Low utility of plasma Nociceptin/orphanin FQ in the diagnosis of hepatocellular carcinoma. World Journal of Gastroenterology 2006; 12(29): 4716-4720 doi: 10.3748/wjg.v12.i29.4716
|
| 43 |
Marianna Franchina, Federica Cavalcoli, Olga Falco, Marta La Milia, Alessandra Elvevi, Sara Massironi. Biochemical Markers for Neuroendocrine Tumors: Traditional Circulating Markers and Recent Development—A Comprehensive Review. Diagnostics 2024; 14(12): 1289 doi: 10.3390/diagnostics14121289
|
| 44 |
Katelin A. Mirkin, Christopher S. Hollenbeak, Joyce Wong. Impact of chromogranin A, differentiation, and mitoses in nonfunctional pancreatic neuroendocrine tumors ≤ 2 cm. Journal of Surgical Research 2017; 211: 206 doi: 10.1016/j.jss.2016.12.033
|
| 45 |
Giulia Malaguarnera, Maria Giordano, Isabella Paladina, Alessandra Rando, Mario Uccello, Francesco Basile, Antonio Biondi, Santo Carnazzo, Innocenza Alessandria, Clorinda Mazzarino. Markers of bile duct tumors. World Journal of Gastrointestinal Oncology 2011; 3(4): 49-59 doi: 10.4251/wjgo.v3.i4.49
|